ZFGN - Zafgen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.04
-0.08 (-1.56%)
As of 2:27PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close5.12
Open5.12
Bid5.05 x 1100
Ask5.05 x 800
Day's Range4.90 - 5.18
52 Week Range3.57 - 12.35
Volume397,936
Avg. Volume347,823
Market Cap185.829M
Beta (3Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-2.01
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.40
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    CURRENT SHAREHOLDERS: Zamansky LLC Investigates Zafgen (ZFGN) for Potential Breaches of Fiduciary Duties

    Zamansky LLC announces that it is investigating Zafgen, Inc. (ZFGN) (“Zafgen” or the “Company”) for potential breaches of fiduciary duties by its officers and board of directors. If you are a shareholder of Zafgen who still holds your shares, please contact our firm for information. It has recently emerged from public filings that Zafgen has received a letter from the U.S. Food and Drug Administration (“FDA”) citing possible cardiovascular safety risks associated with the clinical trial of a new type 2 diabetes drug ZGN-1061 as the reason for placing a clinical hold on the trial.

  • ACCESSWIRE6 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investigation of Zafgen, Inc. (ZFGN)

    NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zafgen, Inc. (''Zafgen'' or the ''Company'') (NASDAQ: ZFGN). ...

  • GlobeNewswire7 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zafgen, Inc. – ZFGN

    Pomerantz LLP is investigating claims on behalf of investors of Zafgen, Inc. (“Zafgen” or the “Company”) (NASDAQ: ZFGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On November 26, 2018, Zafgen announced receipt of a letter from the U.S. Food and Drug Administration (“FDA”) placing a clinical hold on the Investigational New Drug Application for its first U.S. clinical trial of ZGN-1061, the Company’s second-generation, investigational MetAP2 inhibitor currently in development for the treatment of type 2 diabetes.

  • PR Newswire12 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zafgen, Inc. - ZFGN

    NEW YORK , Nov. 28, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zafgen, Inc. ("Zafgen" or the "Company") (NASDAQ: ZFGN).   Such investors are ...

  • Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News
    Zacks12 days ago

    Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News

    Pipeline and regulatory updates are the key highlights in the biotech sector this week.

  • Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial
    Zacks13 days ago

    Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial

    Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.

  • GuruFocus.com13 days ago

    Zafgen: Bargain or Busted?

    Earlier today, shares of Zafgen Inc. (ZFGN) plunged 41% on news that the Food and Drug Administration placed a clinical hold on the company's Investigative New Drug Application (IND) for ZGN-1061, an early-stage candidate drug for the treatment of type 2 diabetes. Zafgen is a clinical-stage biopharmaceutical company specializing in the study of MetAP2 inhibitors in common and rare metabolic disorders. It is currently pursuing research into type 2 diabetes, Prader-Willi syndrome and hepatic diseases.

  • Company News For Nov 27, 2018
    Zacks13 days ago

    Company News For Nov 27, 2018

    Companies In The News Are: ZFGN,CLF,AET,CVS,GWPH

  • ACCESSWIRE13 days ago

    Today's Research Reports on Trending Tickers: Zafgen and Edge Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Zafgen was one of the big decliners in the biotech arena after the FDA put a clinical hold on its Investigational New Drug Application. Shares of Edge Therapeutics were also in the red after announcing a definitive merger agreement with PDS Biotechnology Corporation. Zafgen, Inc. shares sank on Monday nearly 40.5% at the close.

  • Why Aurora Cannabis, Zafgen, and Overstock.com Slumped Today
    Motley Fool14 days ago

    Why Aurora Cannabis, Zafgen, and Overstock.com Slumped Today

    Here's how these stocks missed out on a positive day for the market.

  • Why Zafgen Stock Is Crashing Today
    Motley Fool14 days ago

    Why Zafgen Stock Is Crashing Today

    News of an FDA clinical hold zaps Zafgen's share price.

  • Zafgen shares cut in half after FDA halts diabetes drug trial
    American City Business Journals14 days ago

    Zafgen shares cut in half after FDA halts diabetes drug trial

    Beleaguered Boston biotech Zafgen's stock price was cut nearly in half Monday after it announced that the FDA has halted its plans to begin testing a type 2 diabetes drug.

  • Reuters14 days ago

    U.S. FDA puts Zafgen's diabetes trial on hold

    Zafgen Inc said on Monday the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of its experimental diabetes drug, citing possible heart safety risks. Zafgen said it planned to assess the options put forward by the FDA in a letter last week and request a meeting with the agency to discuss the next steps with the clinical trial.

  • MarketWatch14 days ago

    Zafgen's IND for diabetes treatment placed on hold by FDA

    Zafgen Inc. said Monday the Food and Drug Administration ha placed a clinical hold on its investigational new drug application (IND) for the biopharmaceutical company's first U.S. clinical trial of its type 2 diabetes treatment, citing the possibility of cardiovascular safety risk. The stock was halted for news until 7:30 a.m. Eastern. The FDA outlined multiple potential paths for moving forward, including nonclinical and clinical options to address the concerns. Zafgen said it plans to assess the options and request a Type A meeting with the FDA. Zafgen said that with the delay of additional clinical development for ZGN-1061, the company now expects its cash runway to extend through 2020. The stock has soared 97% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 3.3% and the S&P 500 has lost 1.5%.

  • GlobeNewswire14 days ago

    Zafgen Provides Update on Investigational New Drug Application for ZGN-1061

    Zafgen, Inc. (ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced that the Company received a letter last week from the U.S. Food and Drug Administration (FDA) placing a clinical hold on the Investigational New Drug Application (IND) for its first U.S. clinical trial of ZGN-1061, the Company’s second-generation, investigational MetAP2 inhibitor currently in development for the treatment of type 2 diabetes. The FDA cited the possibility of cardiovascular (CV) safety risk based on the Company’s prior compound and outlined multiple potential paths for moving forward, including nonclinical or clinical options, to address these concerns in the ongoing development of ZGN-1061.

  • GlobeNewswire19 days ago

    Zafgen to Present at the 30th Annual Piper Jaffray Healthcare Conference

    BOSTON, Nov. 21, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of ZFGN earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Zafgen Inc Earnings Call

  • GlobeNewswirelast month

    Zafgen Reports Third Quarter 2018 Operating and Financial Results

    ZGN-1061 1.8 mg cohort for the Phase 2 proof-of-concept trial now fully enrolled; on track for topline results early 2019 ZGN-1258 nonclinical safety and efficacy data sets.

  • GlobeNewswirelast month

    Zafgen to Present at the Stifel 2018 Healthcare Conference

    BOSTON, Nov. 06, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel.

  • GlobeNewswirelast month

    Zafgen to Host Conference Call to Discuss Third Quarter 2018 Financial Results

    BOSTON, Nov. 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel.

  • GlobeNewswire2 months ago

    Zafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference

    Zafgen, Inc. (ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today results from three nonclinical, Investigational New Drug (IND)-enabling studies of ZGN-1258 to be presented at the 2018 Foundation for Prader-Willi Research (FPWR) Family Conference taking place in Las Vegas October 4 – 6, 2018. ZGN-1258 is Zafgen’s second-generation, novel investigational MetAP2 inhibitor for the treatment of rare metabolic disorders, including Prader-Willi syndrome (PWS), designed to decrease hyperphagia, change the way the body metabolizes fat, and reduce fat mass.

  • Simply Wall St.2 months ago

    Who Owns Zafgen Inc (NASDAQ:ZFGN)?

    Every investor in Zafgen Inc (NASDAQ:ZFGN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders Read More...

  • Amarin and Square are among the most important stock charts to watch
    MarketWatch2 months ago

    Amarin and Square are among the most important stock charts to watch

    Amarin and Square have rallied on separate news stories, and both top our charts to watch today, along with two others looking strong technically. Amarin (AMRN) followed through Tuesday, up 60 cents to $13 on huge volume of 106 million shares traded, after surging 300% Monday on news of positive clinical developments.